BG62876B1 - Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост - Google Patents

Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост Download PDF

Info

Publication number
BG62876B1
BG62876B1 BG101803A BG10180397A BG62876B1 BG 62876 B1 BG62876 B1 BG 62876B1 BG 101803 A BG101803 A BG 101803A BG 10180397 A BG10180397 A BG 10180397A BG 62876 B1 BG62876 B1 BG 62876B1
Authority
BG
Bulgaria
Prior art keywords
melatonin
benzodiazepine
treatment
daily
use according
Prior art date
Application number
BG101803A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101803A (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of BG101803A publication Critical patent/BG101803A/xx
Publication of BG62876B1 publication Critical patent/BG62876B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG101803A 1995-02-01 1997-07-30 Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост BG62876B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (2)

Publication Number Publication Date
BG101803A BG101803A (en) 1998-04-30
BG62876B1 true BG62876B1 (bg) 2000-10-31

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101803A BG62876B1 (bg) 1995-02-01 1997-07-30 Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост

Country Status (22)

Country Link
JP (1) JP4516159B2 (lv)
CN (1) CN1083263C (lv)
AT (1) AT408188B (lv)
AU (1) AU695366B2 (lv)
BG (1) BG62876B1 (lv)
BR (1) BR9607169A (lv)
CZ (1) CZ291349B6 (lv)
DK (1) DK176081B1 (lv)
EE (1) EE03384B1 (lv)
FI (1) FI119586B (lv)
IS (1) IS1980B (lv)
LU (1) LU90118B1 (lv)
LV (1) LV11940B (lv)
MD (1) MD1716C2 (lv)
NO (1) NO312814B1 (lv)
NZ (1) NZ298878A (lv)
PL (1) PL183148B1 (lv)
SI (1) SI9620022A (lv)
SK (1) SK284521B6 (lv)
TR (1) TR199700723T1 (lv)
TW (1) TW483757B (lv)
WO (1) WO1996023496A1 (lv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227002B1 (en) 2000-01-05 2010-04-28 Neurim Pharma 1991 Use of melatonin in the manufacture of controlled release medicament for the prevention or treatment of symptoms of hypertension
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CN109922795B (zh) * 2016-10-31 2021-10-08 纽里姆药物有限公司 褪黑素小片剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000073I1 (de) * 1991-05-09 2008-01-31 Neurim Pharma 1991 Melatonin enthaltene Arzneimittel
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
JPH10513177A (ja) 1998-12-15
SI9620022A (sl) 1998-10-31
CN1083263C (zh) 2002-04-24
ATA901396A (de) 2001-02-15
PL183148B1 (pl) 2002-05-31
DK176081B1 (da) 2006-04-18
CZ240597A3 (cs) 1998-01-14
SK103097A3 (en) 1998-01-14
JP4516159B2 (ja) 2010-08-04
AU695366B2 (en) 1998-08-13
MX9705856A (es) 1998-07-31
FI119586B (fi) 2009-01-15
NO312814B1 (no) 2002-07-08
EE9700166A (et) 1998-02-16
CN1172431A (zh) 1998-02-04
MD970254A (en) 1999-05-31
IS1980B (is) 2005-01-14
MD1716B2 (en) 2001-08-31
CZ291349B6 (cs) 2003-02-12
LV11940A (lv) 1998-01-20
BR9607169A (pt) 1997-11-11
BG101803A (en) 1998-04-30
AU4457496A (en) 1996-08-21
TR199700723T1 (xx) 1998-02-21
NO973531D0 (no) 1997-07-31
NZ298878A (en) 1999-05-28
EE03384B1 (et) 2001-04-16
PL321630A1 (en) 1997-12-08
FI973185A0 (fi) 1997-07-31
FI973185A (fi) 1997-09-30
TW483757B (en) 2002-04-21
MD1716C2 (ro) 2002-02-28
IS4532A (is) 1997-07-25
LV11940B (lv) 1998-05-20
DK89697A (da) 1997-07-30
AT408188B (de) 2001-09-25
WO1996023496A1 (en) 1996-08-08
SK284521B6 (sk) 2005-05-05
LU90118B1 (fr) 1997-11-13
NO973531L (no) 1997-09-30

Similar Documents

Publication Publication Date Title
US11241429B2 (en) Method of treating metabolic disorders and depression with dopamine receptor agonists
LT3893B (en) Pharmaceutical composition with nalmefene for treating alcoholism
EP0724878B1 (en) Use of melatonin for treating patients suffering from drug dependencies
US20030008005A1 (en) Sublingual administration of dihydroergotamine for the treatment of migraine
BG62876B1 (bg) Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост
US5830895A (en) Methods for the determination and adjustment of prolactin daily rhythms
EP2138174A1 (en) Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management
Dépôt et al. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans
Linnoila et al. How to antagonize ethanol-induced inebriation
CA2211839C (en) Use of melatonin for treating patients suffering from drug addiction
AU3101395A (en) Improved methods for the determination and adjustment of prolactin daily rhythms
Wurtman Ramelteon: a melatonin receptor agonist
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro
Wasielewski Attenuation of alcohol-induced circadian phase-shifts using melatonin and vitamin B12